TABLE OF CONTENTS
1 INTRODUCTION 85
1.1 OBJECTIVES OF THE STUDY 85
1.2 MARKET DEFINITION 85
1.3 OVERVIEW OF THE EUROPE DYSPEPSIA DRUG MARKET 85
1.4 CURRENCY AND PRICING 87
1.5 LIMITATIONS 87
1.6 MARKETS COVERED 87
2 MARKET SEGMENTATION 91
2.1 MARKETS COVERED 91
2.2 GEOGRAPHICAL SCOPE 92
2.3 YEARS CONSIDERED FOR THE STUDY 93
2.4 DBMR TRIPOD DATA VALIDATION MODEL 94
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 97
2.6 MULTIVARIATE MODELLING 98
2.7 TYPE LIFELINE CURVE 98
2.8 DBMR MARKET POSITION GRID 99
2.9 VENDOR SHARE ANALYSIS 101
2.10 MARKET END-USER COVERAGE GRID 102
2.11 SECONDARY SOURCES 103
2.12 ASSUMPTIONS 103
3 EXECUTIVE SUMMARY 104
4 PREMIUM INSIGHT 107
4.1 PESTEL ANALYSIS 108
4.2 PORTERS FIVE FORCES 109
5 EPIDEMIOLOGY 110
6 PROBLEMS IN THE MANAGEMENT OF DYSPEPSIA 111
7 INDUSTRY INSIGHTS: 112
8 EUROPE DYSPEPSIA DRUG MARKET, REGULATION 113
9 MARKET OVERVIEW 116
9.1 DRIVERS 118
9.1.1 INCREASING PREVALENCE OF DYSPEPSIA 118
9.1.2 RISE IN THE ADOPTION OF UNHEALTHY LIFESTYLE 118
9.1.3 INCREASE IN THE PREVALENCE OF METABOLIC DISORDERS 119
9.2 RESTRAINTS 120
9.2.1 POSSIBLE SIDE EFFECTS OF THE DRUGS USED FOR DYSPEPSIA 120
9.2.2 INCREASING PREFERENCE FOR NATURAL AND HERBAL REMEDIES 121
9.3 OPPORTUNITIES 121
9.3.1 GROWING AGING POPULATION 121
9.3.2 RISE IN THE DRUG APPROVAL 122
9.4 CHALLENGES 123
9.4.1 LACK OF AWARENESS ABOUT DYSPEPSIA AMONG THE POPULATION 123
9.4.2 STRINGENT REGULATIONS 123
10 EUROPE DYSPEPSIA DRUG MARKET, BY TYPE 124
10.1 OVERVIEW 125
10.2 NON-ULCER DYSPEPSIA 128
10.3 ORGANIC DYSPEPSIA 128
10.4 DRUG INDUCED DYSPEPSIA 129
10.5 OTHERS 130
11 EUROPE DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE 131
11.1 OVERVIEW 132
11.2 MEDICATION 135
11.2.1 DRUGS 136
11.2.1.1 ANTACIDS 136
11.2.1.1.1 PROTON PUMP INHIBITORS (PPIS) 136
11.2.1.1.1.1 OMEPRAZOLE 137
11.2.1.1.1.2 LANSOPRAZOLE 137
11.2.1.1.1.3 ESOMEPRAZOLE 137
11.2.1.1.1.4 OTHERS 137
11.2.1.1.2 H2 BLOCKERS 137
11.2.1.1.2.1 CIMETIDINE 138
11.2.1.1.2.2 FAMOTIDINE 138
11.2.1.1.2.3 NIZATIDINE 138
11.2.1.1.2.4 RANITIDINE 138
11.2.1.1.2.5 OTHERS 138
11.2.1.2 GASTRIC PROKINETIC GENDERNTS 138
11.2.1.2.1 MOSAPRIDE CITRATE 139
11.2.1.2.2 METOCLOPRAMIDE 139
11.2.1.2.3 CISAPRIDE 139
11.2.1.2.4 ITOPRIDE HYDROCHLORIDE 139
11.2.1.2.5 DOMPERIDONE 139
11.2.1.2.6 OTHERS 140
11.2.1.3 ANTIBIOTICS 140
11.2.1.3.1 REFAXIMIN 140
11.2.1.3.2 AMOXICILLIN 140
11.2.1.3.3 CLARITHROMYCIN 140
11.2.1.3.4 METRONIDAZOLE 141
11.2.1.3.5 LEVOFLOXACIN 141
11.2.1.3.6 TETRACYCLINE 141
11.2.1.3.7 OTHERS 141
11.2.1.4 OTHERS 141
11.2.2 NON- DRUGS 141
11.2.2.1 PROBIOTICS 141
11.2.2.1.1 LACTOBACILLUS 142
11.2.2.1.2 BIFIDOBACTERIUM 142
11.2.2.1.3 BACILLUS 142
11.2.2.1.4 STREPTOCOCCUS 142
11.2.2.1.5 OTHERS 142
11.2.2.2 PREBIOTICS 142
11.3 SURGERY 143
12 EUROPE DYSPEPSIA DRUG MARKET, BY DRUG TYPE 144
12.1 OVERVIEW 145
12.2 GENERIC 148
12.3 BRANDED 149
13 EUROPE DYSPEPSIA DRUG MARKET, BY PRESCRIPTION 150
13.1 OVERVIEW 151
13.2 WITHOUT PRESCRIPTION DRUGS 154
13.3 PRESCRIPTION DRUGS 155
14 EUROPE DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION 156
14.1 OVERVIEW 157
14.2 ORAL 160
14.2.1 TABLETS 160
14.2.2 CAPSULES 161
14.3 INJECTABLE 161
15 EUROPE DYSPEPSIA DRUG MARKET, BY GENDER 162
15.1 OVERVIEW 163
15.2 FEMALE 166
15.2.1 30-50 YEARS 167
15.2.2 MORE THAN 50 YEARS 167
15.2.3 AGE LESS THAN 30 167
15.3 MALE 167
15.3.1 30-50 YEARS 168
15.3.2 MORE THAN 50 YEARS 168
15.3.3 AGE LESS THAN 30 168
16 EUROPE DYSPEPSIA DRUG MARKET, BY END USER 169
16.1 OVERVIEW 170
16.2 HOSPITALS 173
16.2.1 TYPE 173
16.2.1.1 PUBLIC 174
16.2.1.2 PRIVATE 174
16.2.2 TIER 174
16.2.2.1 TIER 3 174
16.2.2.2 TIER 2 174
16.2.2.3 TEIR 1 174
16.3 CLINICS 174
16.4 HOMECARE SETTINGS 175
16.5 SPECIALTY CLINICS 176
16.6 AMBULATORY CENTERS 177
16.7 ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES 177
16.8 OTHERS 178
17 EUROPE DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL 179
17.1 OVERVIEW 180
17.2 RETAIL SALES 183
17.2.1 REATIL PHARMACY 184
17.2.2 HOSPITAL PHARMACY 184
17.2.3 ONLINE PHARMACY 184
17.3 DIRECT TENDER 184
18 EUROPE DYSPEPSIA DRUG MARKET, BY REGION 185
18.1 EUROPE 186
18.1.1 GERMANY 200
18.1.2 U.K. 210
18.1.3 ITALY 220
18.1.4 FRANCE 230
18.1.5 SPAIN 240
18.1.6 RUSSIA 250
18.1.7 SWITZERLAND 260
18.1.8 TURKEY 270
18.1.9 BELGIUM 280
18.1.10 NETHERLANDS 290
18.1.11 DENMARK 300
18.1.12 SWEDEN 310
18.1.13 POLAND 320
18.1.14 NORWAY 330
18.1.15 FINLAND 340
18.1.16 REST OF EUROPE 350
19 EUROPE DYSPEPSIA DRUG MARKET, COMPANY LANDSCAPE 351
19.1 COMPANY SHARE ANALYSIS: EUROPE 351
20 SWOT ANALYSIS 352
21 EUROPE DYSPEPSIA DRUG MARKET, COMPANY PROFILINGS 353
21.1 SANOFI 353
21.1.1 COMPANY SNAPSHOT 353
21.1.2 REVENUE ANALYSIS 353
21.1.3 COMPANY SHARE ANALYSIS 354
21.1.4 PRODUCT PORTFOLIO 354
21.1.5 RECENT DEVELOPMENT 354
21.2 LUPIN 355
21.2.1 COMPANY SNAPSHOT 355
21.2.2 REVENUE ANALYSIS 355
21.2.3 COMPANY SHARE ANALYSIS 356
21.2.4 PRODUCT PORTFOLIO 356
21.2.5 RECENT DEVELOPMENTS 356
21.3 MANKIND PHARMA 357
21.3.1 COMPANY SNAPSHOT 357
21.3.2 REVENUE ANALYSIS 357
21.3.3 COMPANY SHARE ANALYSIS 358
21.3.4 PRODUCT PORTFOLIO 358
21.3.5 RECENT DEVELOPMENT 358
21.4 ASTRAZENECA 359
21.4.1 COMPANY SNAPSHOT 359
21.4.2 REVENUE ANALYSIS 359
21.4.3 COMPANY SHARE ANALYSIS 360
21.4.4 PRODUCT PORTFOLIO 360
21.4.5 RECENT DEVELOPMENT 360
21.5 BAYER AG 361
21.5.1 COMPANY SNAPSHOT 361
21.5.2 REVENUE ANALYSIS 361
21.5.3 COMPANY SHARE ANALYSIS 362
21.5.4 PRODUCT PORTFOLIO 362
21.5.5 RECENT DEVELOPMENT 362
21.6 ABBOTT 363
21.6.1 COMPANY SNAPSHOT 363
21.6.2 REVENUE ANALYSIS 363
21.6.3 PRODUCT PORTFOLIO 364
21.6.4 RECENT DEVELOPMENT 364
21.7 ANI PHARMACEUTICALS, INC. 365
21.7.1 COMPANY SNAPSHOT 365
21.7.2 REVENUE ANALYSIS 365
21.7.3 PRODUCT PORTFOLIO 366
21.7.4 RECENT DEVELOPMENT 366
21.8 AOSAIKANG PHARMACEUTICAL CO., LTD. 367
21.8.1 COMPANY SNAPSHOT 367
21.8.2 REVENUE ANALYSIS 367
21.8.3 PRODUCT PORTFOLIO 368
21.8.4 RECENT DEVELOPMENT 368
21.9 ASTERISK LABORATORIES (I) PVT. LTD 369
21.9.1 COMPANY SNAPSHOT 369
21.9.2 PRODUCT PORTFOLIO 369
21.9.3 RECENT DEVELOPMENT 369
21.10 CADILA PHARMACEUTICALS 370
21.10.1 COMPANY SNAPSHOT 370
21.10.2 REVENUE ANALYSIS 370
21.10.3 COMPANY SHARE ANALYSIS 371
21.10.4 PRODUCT PORTFOLIO 371
21.10.5 RECENT DEVELOPMENT 371
21.11 HANMI PHARM. CO., LTD. 372
21.11.1 COMPANY SNAPSHOT 372
21.11.2 REVENUE ANALYSIS 372
21.11.3 PRODUCT PORTFOLIO 373
21.11.4 RECENT DEVELOPMENT 373
21.12 MCNEIL CONSUMER PHARMACEUTICALS CO. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.) 374
21.12.1 COMPANY SNAPSHOT 374
21.12.2 REVENUE ANALYSIS 374
21.12.3 PRODUCT PORTFOLIO 375
21.12.4 RECENT DEVELOPMENT 375
21.13 OTSUKA PHARMACEUTICAL CO., LTD. 376
21.13.1 COMPANY SNAPSHOT 376
21.13.2 REVENUE ANALYSIS 376
21.13.3 PRODUCT PORTFOLIO 377
21.13.4 RECENT DEVELOPMENT 377
21.14 PERRIGO COMPANY PLC 378
21.14.1 COMPANY SNAPSHOT 378
21.14.2 REVENUE ANALYSIS 378
21.14.3 PRODUCT PORTFOLIO 379
21.14.4 RECENT DEVELOPMENT 379
21.15 PRESTIGE CONSUMER HEALTHCARE, INC. 380
21.15.1 COMPANY SNAPSHOT 380
21.15.2 REVENUE ANALYSIS 380
21.15.3 PRODUCT PORTFOLIO 381
21.15.4 RECENT DEVELOPMENT 381

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.